RNS Number: 8595 R Silence Therapeutics PLC 02 July 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
The Company announced on 23 June 2020 that it had confidentially submitted a registration statement to the U.S. Securities and Exchange Commission in connection with a proposed listing of American Depositary Shares representing the Company's ordinary shares on the Nasdaq Capital Market.. 2. the U.S. Employee Sub-Plan to the Employee LTIP which permits the...
RNS Number: 5576 R Silence Therapeutics PLC 30 June 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 4306 R Silence Therapeutics PLC 29 June 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Silence Therapeutics Submits Registration Statement to the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares. LONDON, Silence Therapeutics plc, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces it has confidentially submitted a registration...
RNS Number: 7278 Q Silence Therapeutics PLC 23 June 2020 Business Update. LONDON, Silence Therapeutics plc, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today provides a mid-year business update. The Company has today separately announced that it has confidentially submitted a...
RNS Number: 5939 P Silence Therapeutics PLC 10 June 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 4599 P Silence Therapeutics PLC 10 June 2020. London, 10 th June 2020. Silence Therapeutics plc, AIM: SLN a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that at its Annual General Meeting held on Tuesday, 9 th June 2020, all resolutions set out in the...
RNS Number: 1653 P Silence Therapeutics PLC 05 June 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5883 O Silence Therapeutics PLC 01 June 2020. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 30,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
RNS Number: 3659 O Silence Therapeutics PLC 29 May 2020 PDMR Shareholding. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that on May 28th 15,800 Shares were purchased by Iain Ross, Executive Chairman of the Company, through his SIPP at £4.70...
RNS Number: 6713 N Silence Therapeutics PLC 21 May 2020 Grant of Share Options. LONDON, Silence Therapeutics, PLC, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, advises that on 20 May 2020 new options have been issued to Iain Ross, Executive Chairman, to acquire a total of 500,000 new ordinary...
Silence Therapeutics Plc (SLN.L) Announced that it intends to confidentially submit a registration statement to the United States Securities and Exchange Commission (SEC) in connection with a proposed listing of American Depositary Shares (ADSs) representing the company's ordinary shares on the Nasdaq Stock Market (Nasdaq). Separately, the company has announced the appointment of Investec Bank plc as the Company's Nominated Adviser and sole Broker, effective immediately. Separately, Iain Ross has agreed to become full time Executive Chairman in order to implement and oversee a number of key positive company initiatives in the near future. Moreover, Dr. Giles Campion would become an Executive Director of the company with immediate effect. #SLN
RNS Number: 4054 N Silence Therapeutics PLC 20 May 2020 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
RNS Number: 4056 N Silence Therapeutics PLC 20 May 2020 Appointment of New Nominated Adviser and Broker. LONDON, Silence Therapeutics plc, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces the appointment of Investec Bank plc as the Company's Nominated Adviser and sole Broker,...
RNS Number: 4057 N Silence Therapeutics PLC 20 May 2020 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION. Silence Therapeutics Announces Intent to Submit Registration Statement to the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing...
RNS Number: 8368 M Silence Therapeutics PLC 14 May 2020 Silence Therapeutics to Participate in Fireside Chat at the RBC Capital Markets Global Healthcare Virtual Conference. LONDON, Silence Therapeutics plc, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that Dr.
RNS Number: 6828 M Silence Therapeutics PLC 12 May 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6252 M Silence Therapeutics PLC 12 May 2020 PDMR Dealing. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces the following share trades by Dr. Rob Quinn, Chief Financial Officer of the Company..
RNS Number: 1966 M Silence Therapeutics PLC 07 May 2020 Silence Therapeutics Notice of Annual General Meeting. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that t his year's Annual General Meeting of the Company will be held on 9 June 2020 at...
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    78.37M

Income Statement

Sales/Revenue
Gross Income
Operating Income
Net Interest Income
Pre-Tax Income
Consolidated Net Income
Non-Interest Income
Interest Income after Loan Loss Provision
Non-Operating Income
Operating Income (EBIT)
Net Income
Non-Interest Expense
Operating Expenses
Total Expense
Operating profit per share
EPS (Basic)
EPS (Diluted - Before Unusual Expense)
EPS (Fully Diluted)

Balance Sheet - Assets

Net Property, Plant & Equipment
Intangible Assets
Cash & Short Term Investments
Investments
Other Financial Assets
Inventories
Total Short Term Accounts Receivable
Total Accounts Receivable
Total Cash & Due from Banks
Premium Balance Receivables
Total Current Assets
Tangible Other Assets
Other Intangible Assets
Other Assets
Other Funds
Total Assets

Balance Sheet - Liabilities

Liabilities & Stockholders' Equity
Other Current Liabilities
Total Current Liabilities
Provision for Risks & Charges
Losses, Claims & Reserves
Other Liabilities
Total Liabilities

Balance Sheet - Other

Dividends Per Share (Gross)
Dividends Per Share
Dividends Per Share (1-yr Annual Growth)
Dividend payout per share
Common Shares
Common Shares Outstanding
Common Shares (EPS Basic)
Common Shares (EPS Diluted)
Closely Held Shares
Total Shareholders' Equity
Non-Equity Reserves
Retained Earnings
Total Equity
Pre-Tax Margin
Net Interest Margin
Gross Profit Margin
Net Margin
Operating Margin
P/E Ratio
Debt / EBITDA
Total Debt / Assets
Assets Per Employee
Current Ratio
Common Stock Par / Carry Value
Enterprise Value
Market Value
Market Capitalisation
Dividend Yield
Dividend Yield - Security
Cash Dividend Coverage Ratio

Miscellaneous

Total Debt
Restricted Cash
Exchange Rate Effect
Incomes Taxes
Net Change in Cash
Income Tax Payable
Cash Only
Cash Dividends Paid
Convertible Debt
Long Term Debt
Short Term Debt
Asset Turnover
EBITDA
Operating Income After Interest Expense
Net Debt
Operating Income Before Interest Expense
Purchase / Sale of Investments
Other Appropriated Reserves
Creditors
Watchlist